SCHEMBL7922936

SCHEMBL7922936

CCCCCCCC[C@H]1CC[C@H](C(=O)O)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.57
HTT P42858 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
PKM P14618 1/20 0.54
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
LMNA P02545 2/20 0.48
PLG P00747 1/20 0.48
PLAT P00750 1/20 0.48
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
MAPT P10636 1/20 0.46
CCR2 P41597 1/20 0.45
ALOX5 P09917 1/20 0.44
S1PR3 Q99500 2/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8975282 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL9190477 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL2441406 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL10141498 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL3472519 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL9196316 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL24919991 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL9190483 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL1896639 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM
SCHEMBL8435960 1.00 TP53 (0.57) TP53HTTMEN1KMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
EP-0814073-B1 Epimerization of 2- or 4-substituted cyclohexanecarboxylic acids KATAYAMA SEISAKUSHO (JP) 2001-09-12 EP disclosed
US-5831118-A HEATING WITH POTASSIUM HYDROXIDE; ONE STEP KATAYAMA SEIYAKUSYO CO., LTD. (JP) 1998-11-03 US disclosed
EP-0814073-A1 Epimerization of 2- or 4-substituted cyclohexanecarboxylic acids KATAYAMA SEIYAKUSYO CO. Ltd. (JP) 1997-12-29 EP disclosed
EP-0394906-B1 Liquid crystalline composition MERCK PATENT GMBH (DE) 1995-12-20 EP disclosed
EP-0315958-B1 OPTICALLY ACTIVE MESOMORPHIC COMPOUND AND LIQUID CRYSTAL COMPOSITION CONTAINING SAME CANON KABUSHIKI KAISHA (JP) 1993-03-10 EP disclosed
US-5182047-A FLUORINATED BIPHENYLDIOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1993-01-26 US disclosed
EP-0368975-B1 FLUORINATED BIPHENYLDIOLE DERIVATIVES MERCK PATENT GmbH (DE) 1992-12-16 EP disclosed
EP-0394906-A2 Liquid crystalline composition MERCK PATENT GmbH (DE) 1990-10-31 EP disclosed
EP-0368975-A1 FLUORINATED BIPHENYLDIOLE DERIVATIVES. MERCK PATENT GMBH (DE) 1990-05-23 EP disclosed
US-4917821-A Optically active mesomorphic compound and liquid crystal composition containing same CANON KABUSHIKI KAISHA (JP) 1990-04-17 US disclosed
WO-1989012039-A1 FLUORINATED BIPHENYLDIOLE DERIVATIVES MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1989-12-14 WO disclosed
EP-0315958-A2 Optically active mesomorphic compound and liquid crystal composition containing same CANON KABUSHIKI KAISHA (JP) 1989-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 TP53 4394/4885HTT 3363/4885MEN1 4363/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 TP53 4394/4885HTT 3363/4885MEN1 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.